Breaking from the herd
New advances in PD-1 combinations, sarcoma treatments and nucleotides at ASCO
Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such as how to turn cold tumors hot, how to deploy new modalities and how to broaden responsiveness to immunotherapies.
BioCentury’s third annual survey of abstracts at the American Society of Clinical Oncology (ASCO) meeting presents a snapshot of clinical research in cancer, according to a machine learning-based analysis of 3,444 abstracts for mentions of products, indications, targets, modalities or other specialized terms...
BCIQ Company Profiles